Activartis’ Cancer Immunotherapy Receives Orphan Drug Designation from FDA

News   Jul 01, 2013

 
Activartis’ Cancer Immunotherapy Receives Orphan Drug Designation from FDA
 
 
 

RELATED ARTICLES

Two Studies Provide Significant Hope in the Fight Against Antibiotic Resistance

News

Two recent studies led by the University of Bristol provide significant new hope in the fight against antibiotic resistance.

READ MORE

Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until Now

News

A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.

READ MORE

Sekisui XenoTech Appoints New COO

News

Company hires CRO & pharma veteran, Dr. Darren Warren, as new Chief Operating Officer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE